Medical technology firm Simulations Plus (NASDAQ: SLP) reported a strong second quarter for 2026, with revenues reaching $24.3 million, an 8% increase year-over-year. The company’s software revenue rose 9% to $14.6 million, driven by demand for its discovery and development solutions. Net income, adjusted for GAAP, also exceeded expectations, climbing 13% to $7 million, or $0.35 per share, surpassing analyst estimates for both revenue and profit.
However, investor enthusiasm was tempered by a reduction in full-year adjusted net income guidance, now projected between $0.75 and $0.85 per share, down from an earlier forecast of $1.03 to $1.10, attributed to a higher effective tax rate. Despite this, revenue guidance remains steady at $79 million to $82 million, indicating stability in the company’s core operations.
For market professionals, the key takeaway is that while the guidance cut may raise caution, the underlying business momentum and solid quarterly performance suggest potential for growth, positioning Simulations Plus as a compelling buy opportunity in the healthcare tech sector.
Source: fool.com